Prasugrel Superior to Ticagrelor in ACS Patients Who Undergo PCI, According to an ISAR-REACT 5 Trial Subgroup Analysis
In a prespecified subgroup analysis of patients from the ISAR-REACT 5 trial, those with acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI) and who received prasugrel saw lower rates of the composite primary outcome of all-cause mortality, myocardial infarction (MI) and stroke at 12 months compared to those who received ticagrelor.